Discover recent press, blog posts and announcements from Sequoia.

News

Sequoia Reinsurance Services offers a portfolio of reinsurance solutions to support companies as they work to manage medical risk and contain costs.

Sarepta Duchenne gene therapy wins broader use from FDA

Sarepta Duchenne gene therapy wins broader use from FDA

Click here to download PDF

READ MORE
The Dangers, Cost of Weight Loss Drugs and How to Avoid a “Life Sentence” of Dependency On Them

The Dangers, Cost of Weight Loss Drugs and How…

Click here to download PDF

READ MORE
Bristol Myers secures another FDA go-ahead for Breyanzi, this time in mantle cell lymphoma

Bristol Myers secures another FDA go-ahead for Breyanzi, this…

Click here to download PDF

READ MORE
BMS CAR-T Therapy Wins FDA Approval for Expanded Use in Follicular Lymphoma

BMS CAR-T Therapy Wins FDA Approval for Expanded Use…

Click here to download PDF

READ MORE
Pfizer will charge $3.5M for its first FDA- approved gene therapy

Pfizer will charge $3.5M for its first FDA- approved…

Click here to download PDF

READ MORE
FDA Greenlights BMS, J&J CAR-T Therapies for Earlier Multiple Myeloma Treatment

FDA Greenlights BMS, J&J CAR-T Therapies for Earlier Multiple…

Click here to download PDF

READ MORE
Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy

Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene…

Click here to download PDF

READ MORE
U.S. FDA Approves Bristol Myers Squibb’s Breyanzi ® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

U.S. FDA Approves Bristol Myers Squibb’s Breyanzi ® as…

Click here to download PDF

READ MORE
US FDA grants accelerated approval for Iovance’s skin cancer therapy

US FDA grants accelerated approval for Iovance’s skin cancer…

Click here to download PDF

READ MORE
Vertex, CRISPR’s gene-editing therapy Casgevy wins early FDA nod to treat beta thalassemia

Vertex, CRISPR’s gene-editing therapy Casgevy wins early FDA nod…

Click here to download PDF

READ MORE
FDA approves world’s first CRISPR-based medicine for sickle cell

FDA approves world’s first CRISPR-based medicine for sickle cell

Click here to download PDF

READ MORE
Self Insurer – Wellness Program RESET

Self Insurer – Wellness Program RESET

Click here to download PDF

READ MORE
Sequoia and IOA Re Announce Expansion into Personal Accident Reinsurance Sector

Sequoia and IOA Re Announce Expansion into Personal Accident…

Leading medical stop loss and managed care writers expand product offering with Everest

READ MORE
The Sequoia Branch Advisory Statement on Claim Payment Integrity

The Sequoia Branch Advisory Statement on Claim Payment Integrity

Click here to download PDF

READ MORE
Mesoblast Plans New GvHD Trial After Another FDA Rejection

Mesoblast Plans New GvHD Trial After Another FDA Rejection

Click here to download PDF

READ MORE
FDA blesses CellTrans’ Lantidra, the first cell therapy for Type 1 diabetes

FDA blesses CellTrans’ Lantidra, the first cell therapy for…

Click here to download PDF

READ MORE
BioMarin finally secures FDA approval of hemophilia gene therapy

BioMarin finally secures FDA approval of hemophilia gene therapy

Click here to download PDF

READ MORE
First Duchenne gene therapy approved by FDA for young children

First Duchenne gene therapy approved by FDA for young…

Click here to download PDF

READ MORE
Self Insurer – Employers Prioritize Behavioral Health

Self Insurer – Employers Prioritize Behavioral Health

Click here to download PDF

READ MORE
FDA approves Krystal gene therapy for rare wound disorder

FDA approves Krystal gene therapy for rare wound disorder

Click here to download PDF

READ MORE
NSM Insurance Group Acquires ELMC Subsidiaries from J.C. Flowers to Establish Platform in Medical Stop Loss and Managed Care Space

NSM Insurance Group Acquires ELMC Subsidiaries from J.C. Flowers…

Click here to download PDF

READ MORE
US allows use of Gamida’s therapy in blood cancer treatment

US allows use of Gamida’s therapy in blood cancer…

Click here to download PDF

READ MORE
Ferring Receives Approval from U.S. FDA for Adstiladrin for High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Ferring Receives Approval from U.S. FDA for Adstiladrin for…

Click here to download PDF

READ MORE
Self Insurer – Inflation Impacts Healthcare Costs and Self-Insured Benefit Plans

Self Insurer – Inflation Impacts Healthcare Costs and Self-Insured…

Click here to download PDF

READ MORE
Australia’s CSL prices hemophilia gene therapy at $3.5 million

Australia’s CSL prices hemophilia gene therapy at $3.5 million

Click here to download PDF

READ MORE
FDA approves J&J’s BCMA-targeted bispecific for multiple myeloma

FDA approves J&J’s BCMA-targeted bispecific for multiple myeloma

Click here to download PDF

READ MORE
Self Insurer – Stop Loss companies and reinsurers help employers tackle key market challenges

Self Insurer – Stop Loss companies and reinsurers help…

Click here to download PDF

READ MORE
Bluebird wins FDA approval of gene therapy for rare brain disorder

Bluebird wins FDA approval of gene therapy for rare…

Click here to download PDF

READ MORE
Bluebird’s $2.8 million gene therapy becomes most expensive drug after U.S. approval

Bluebird’s $2.8 million gene therapy becomes most expensive drug…

The U.S. Food and Drug Administration on Wednesday approved bluebird bio’s (BLUE.O) gene therapy for patients with a rare disorder…

READ MORE
SIIA- Reinsurance Market Update

SIIA- Reinsurance Market Update

Click here to download PDF

READ MORE
Bristol’s Breyanzi wins broader FDA nod, bringing CAR-T showdown with Gilead to earlier lymphoma

Bristol’s Breyanzi wins broader FDA nod, bringing CAR-T showdown…

The FDA has cleared Breyanzi to treat newly relapsed or refractory large B-cell lymphoma, less than three months after Yescarta…

READ MORE
BioMarin Delays Planned FDA Filing

BioMarin Delays Planned FDA Filing

Click here to download PDF

READ MORE
Medicaid Best Price 101

Medicaid Best Price 101

Click here to download PDF

READ MORE
Yescarta® Receives U.S. FDA Approval as First CAR T-cell Therapy for Initial Treatment of Relapsed or Refractory Large B-cell Lymphoma (LBCL)

Yescarta® Receives U.S. FDA Approval as First CAR T-cell…

Click here to download PDF

READ MORE
Sequoia – Cell & Gene Therapy Risk Solutions

Sequoia – Cell & Gene Therapy Risk Solutions

Click here to download PDF

READ MORE
Sequoia Branch Bill Review Extended ICU LOS

Sequoia Branch Bill Review Extended ICU LOS

Sequoia Branch Bill Review Extended ICU LOS

READ MORE
Phase 3 Trial of Hemophilia A Gene Therapy SB-525

Phase 3 Trial of Hemophilia A Gene Therapy SB-525

Phase 3 Trial of Hemophilia A Gene Therapy SB-525

READ MORE
Sequoia Branch Oncology Claims Negotiation

Sequoia Branch Oncology Claims Negotiation

Sequoia Branch Oncology Claims Negotiation

READ MORE
Novartis’ Kymriah fails to meet primary goal in non-Hodgkin lymphoma trial

Novartis’ Kymriah fails to meet primary goal in non-Hodgkin…

Novartis’ Kymriah fails to meet primary goal in non-Hodgkin lymphoma trial

READ MORE
New data show BioMarin’s troubled hemophilia gene therapy continues to fade, opening room for rivals – Endpoints News

New data show BioMarin’s troubled hemophilia gene therapy continues…

New data show BioMarin’s troubled hemophilia gene therapy continues to fade, opening room for rivals – Endpoints News

READ MORE
Bluebird cleared by FDA to resume studies of sickle cell gene therapy – BioPharma Dive

Bluebird cleared by FDA to resume studies of sickle…

Bluebird cleared by FDA to resume studies of sickle cell gene therapy

READ MORE
FDA approval sets stage for a showdown between Alexion and Apellis BioPharma Dive

FDA approval sets stage for a showdown between Alexion…

FDA approval sets stage for a showdown between Alexion and Apellis BioPharma Dive

READ MORE
FDA approves ADC Therapeutics antibody drug conjugate in B-cell lymphoma – MedCity News

FDA approves ADC Therapeutics antibody drug conjugate in B-cell…

FDA approves ADC Therapeutics antibody drug conjugate in B-cell lymphoma - MedCity News

READ MORE
U.S. Food and Drug Administration Approves Bristol Myers Squibbs and bluebird bios Abecma (idecabtagene vicleucel) the First Anti-BCMA CAR T Cell Therapy for Relapse

U.S. Food and Drug Administration Approves Bristol Myers Squibbs…

U.S. Food and Drug Administration Approves Bristol Myers Squibbs and bluebird bios Abecma (idecabtagene vicleucel)

READ MORE
Gilead’s Kite keeps adding to CAR-T Yescarta’s bag of tricks with FDA approval in follicular lymphoma — a first – Endpoints News

Gilead’s Kite keeps adding to CAR-T Yescarta’s bag of…

Gilead’s Kite keeps adding to CAR-T Yescarta’s bag of tricks

READ MORE
Bristol Myers finally wins FDA approval for cancer cell therapy _ BioPharma Dive

Bristol Myers finally wins FDA approval for cancer cell…

Bristol Myers finally wins FDA approval for cancer cell therapy

READ MORE
CMS Issues Final Rule to Empower States, Manufacturers, and Private Payers to Create New Payment Methods for Innovative New Therapies Based on Patient Outcomes _ CMS

CMS Issues Final Rule to Empower States, Manufacturers, and…

CMS Issues Final Rule to Empower States, Manufacturers, and Private Payers

READ MORE
Sequoia Branch Industry Leading Client Savings 2020

Sequoia Branch Industry Leading Client Savings 2020

Sequoia Branch Industry Leading Client Savings 2020

READ MORE
Sequoia Reinsurance Services LLC Announces Agreement with Everest Reinsurance Company

Sequoia Reinsurance Services LLC Announces Agreement with Everest Reinsurance…

Click here to download PDF.

READ MORE
Sequoia Branch CAR T-Cell Insights

Sequoia Branch CAR T-Cell Insights

Click here to download PDF.

READ MORE
Sequoia Underwriting Administrator Announcement

Sequoia Underwriting Administrator Announcement

Click here to download PDF.

READ MORE
COVID-19 Case Branch Savings

COVID-19 Case Branch Savings

COVID-19 Case Branch Savings

READ MORE
NICU Case Branch Savings

NICU Case Branch Savings

NICU Case Branch Savings

READ MORE
COVID Patients Testing Positive

COVID Patients Testing Positive

COVID Patients Testing Positive

READ MORE
Sequoia Presents: The Impact of COVID-19 – Focused Claims Review with Optum

Sequoia Presents: The Impact of COVID-19 – Focused Claims…

Sequoia Presents: The Impact of COVID-19 - Focused Claims Review with Optum

READ MORE
How Much More Than Medicare

How Much More Than Medicare

How Much More Than Medicare

READ MORE
Potential Costs of Coronavirus Treatment

Potential Costs of Coronavirus Treatment

Potential Costs of Coronavirus Treatment

READ MORE
Mass. Outlines Deal For A $2 Million Drug: Pay Only If It Works

Mass. Outlines Deal For A $2 Million Drug: Pay…

Mass. Outlines Deal For A $2 Million Drug: Pay Only If It Works

READ MORE
Reinsurance Market Risk Drivers and Pipeline 2020

Reinsurance Market Risk Drivers and Pipeline 2020

Provided Content is password protected. Click Read More!

READ MORE
Branch Claim Payment Integrity Review

Branch Claim Payment Integrity Review

Branch Claim Payment Integrity Review

READ MORE
Accessibility and Affordability of Gene Therapy

Accessibility and Affordability of Gene Therapy

Accessibility and Affordability of Gene Therapy

READ MORE
Doctor offers unique perspective as father of a child with rare genetic disease

Doctor offers unique perspective as father of a child…

Doctor offers unique perspective as father of a child with rare genetic disease

READ MORE
Market Insight Specialty Pharmacy

Market Insight Specialty Pharmacy

Market Insight Specialty Pharmacy

READ MORE
Market Insight Gene and Immuno – Therapy

Market Insight Gene and Immuno – Therapy

Market Insight Gene and Immuno - Therapy

READ MORE
Long Term Acute Care (LTAC) Hospitals

Long Term Acute Care (LTAC) Hospitals

Long Term Acute Care (LTAC) Hospitals

READ MORE
Market Insight-Hemophilia

Market Insight-Hemophilia

Market Insight-Hemophilia

READ MORE
Market Insight ICER Pharmacy Rebates

Market Insight ICER Pharmacy Rebates

Market Insight ICER Pharmacy Rebates

READ MORE
Sequoia Reinsurance Launches, Focused on HMO Reinsurance and Provider Excess; Backed by ELMC Risk Solutions

Sequoia Reinsurance Launches, Focused on HMO Reinsurance and Provider…

MINNEAPOLIS, June 14, 2018 /PRNewswire/ — Sequoia Reinsurance LLC (“Sequoia”) announced today that it has launched operations focused on HMO reinsurance and provider…

READ MORE
New Reinsurance Firm to Offer Some Employer Stop-Loss

New Reinsurance Firm to Offer Some Employer Stop-Loss

A new, Minneapolis-based health reinsurance firm says it will offer specialized employer stop-loss arrangements, without defining exactly what those arrangements…

READ MORE
Something Happened to U.S. Drug Costs in the 1990s

Something Happened to U.S. Drug Costs in the 1990s

Two decades ago, the costs began rising well beyond that of other nations, and in recent years have shot up…

READ MORE
Branch Program Claim Payment Integrity Review

Branch Program Claim Payment Integrity Review

Branch Program Claim Payment Integrity Review

READ MORE